Fera Acquires Rights to Seven Fougera Ophthalmic Drug Applications

16 July 2009 (Last Updated July 16th, 2009 18:30)

Fera Pharmaceuticals has acquired all rights, title and interest to seven prescription ophthalmic abbreviated new drug applications marketed by Fougera, a division of Nycomed. The sterile anti-infective ophthalmic products awaiting approval include Bacitracin; Bacitracin Zinc and Polymixi

Fera Pharmaceuticals has acquired all rights, title and interest to seven prescription ophthalmic abbreviated new drug applications marketed by Fougera, a division of Nycomed.

The sterile anti-infective ophthalmic products awaiting approval include Bacitracin; Bacitracin Zinc and Polymixin B Sulfate; Gentamicin Sulfate, Neomycin and Polymyxin B Sulfates and Bacitracin Zinc; Neomycin and Polymyxin B Sulfates and Dexamethasone; Neomycin and Polymyxin B Sulfates, Bacitracin Zinc and Hydrocortisone Acetate, as well Erythromycin Ophthalmic Ointments USP.

A Fera spokesperson said that the company was pleased to be able to help meet the market demand for these important products and continue to provide physicians, pharmacies and patients with more options when treating ocular infections.

Fera is already accepting orders for Bacitracin and plans to ship in September 2009 and will also be distributing limited inventories of Fougera labelled Bacitracin while initiating technical transfers and obtaining required regulatory approvals for the rest of the line.

It is anticipated that Fera labelled products will be available in early 2010.